Evidence – Improving Confidence in Glioblastoma Development by Understanding What Truly Predicts Clinical Success

• Exploring why glioblastoma programmes continue to fail despite apparently encouraging preclinical data and examining the differences between marginal and clinically meaningful efficacy signals
• Evaluating the predictive value of orthotopic and translational tumour models to better understand which preclinical outcomes are most strongly associated with clinical success
• Applying lessons learned from glioblastoma development programmes to improve candidate selection, strengthen translational confidence, and avoid progression decisions based on weak or misleading data

Speakers:

Adam Robertson

Chief Scientific Officer

Hemispherian